This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schumer, S. T. Articles by Cannistra, S. A. Search for Related Content PubMed PubMed Citation Articles by Schumer, S. T. Articles by Cannistra, S. A.

Granulosa Cell Tumor of the Ovary

From the Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA.

Address reprint requests to Stephen A. Cannistra, MD, Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215; email: scannist{at}caregroup.harvard.edu.

Adult granulosa cell tumor (GCT) of the ovary is oftentimes a hormonally active, stromal cell neoplasm that is distinguished by its ability to secrete sex steroids such as estrogen. Patients may present with vaginal bleeding caused by endometrial hyperplasia or uterine cancer as a result of prolonged exposure to tumor-derived estrogen. In addition, GCT is a vascular tumor that may occasionally rupture and result in abdominal pain, hemoperitoneum, and hypotension, mimicking an ectopic pregnancy in younger patients. GCT is usually associated with a mass on pelvic examination that is subsequently confirmed on ultrasonography. Surgery is required for definitive tissue diagnosis, staging, and tumor debulking. In older women, a total abdominal hysterectomy and bilateral salpingooophorectomy are typically performed. In women of childbearing age, a more conservative unilateral salpingo-oophorectomy may be performed, assuming that careful staging reveals that the disease has not extended outside of the involved ovary and that a concomitant uterine cancer has been excluded. Survival of patients with GCT is generally excellent because most patients present with early-stage disease, although certain high-risk patient groups may be identified. Stage is the most important prognostic factor, with a higher risk of relapse being associated with stages II through IV disease. In addition, patients with stage I disease associated with features such as large tumor size, high mitotic index, or tumor rupture may also be at higher risk in some series. The value of postoperative adjuvant therapy for high-risk patients has not been investigated by prospective randomized trials, which are difficult to perform because of the rarity of this tumor. Nonetheless, the use of adjuvant chemotherapy or radiation has sometimes been associated with prolonged disease-free survival in patients with high-risk features. Because of the propensity of GCT to recur years after initial diagnosis, prolonged surveillance with serial physical examination and serum tumor markers such as estradiol and inhibin is reasonable.

This article has been cited by other articles:

				R. S. Viger, S. M. Guittot, M. Anttonen, D. B. Wilson, and M. Heikinheimo Role of the GATA Family of Transcription Factors in Endocrine Development, Function, and Disease Mol. Endocrinol., April 1, 2008; 22(4): 781 - 798. [Abstract] [Full Text] [PDF]

				N. Colombo, G. Parma, V. Zanagnolo, and A. Insinga Management of Ovarian Stromal Cell Tumors J. Clin. Oncol., July 10, 2007; 25(20): 2944 - 2951. [Abstract] [Full Text] [PDF]

				N. Kalfa, A. Ecochard, C. Patte, P. Duvillard, F. Audran, C. Pienkowski, E. Thibaud, R. Brauner, C. Lecointre, D. Plantaz, et al. Activating Mutations of the Stimulatory G Protein in Juvenile Ovarian Granulosa Cell Tumors: A New Prognostic Factor? J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1842 - 1847. [Abstract] [Full Text] [PDF]

				D. Boerboom, L. D. White, S. Dalle, J. Courty, and J. S. Richards Dominant-Stable {beta}-Catenin Expression Causes Cell Fate Alterations and Wnt Signaling Antagonist Expression in a Murine Granulosa Cell Tumor Model Cancer Res., February 15, 2006; 66(4): 1964 - 1973. [Abstract] [Full Text] [PDF]

				M. Anttonen, L. Unkila-Kallio, A. Leminen, R. Butzow, and M. Heikinheimo High GATA-4 Expression Associates with Aggressive Behavior, whereas Low Anti-Mullerian Hormone Expression Associates with Growth Potential of Ovarian Granulosa Cell Tumors J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6529 - 6535. [Abstract] [Full Text] [PDF]

				D. Boerboom, M. Paquet, M. Hsieh, J. Liu, S. P. Jamin, R. R. Behringer, J. Sirois, M. M. Taketo, and J. S. Richards Misregulated Wnt/{beta}-Catenin Signaling Leads to Ovarian Granulosa Cell Tumor Development Cancer Res., October 15, 2005; 65(20): 9206 - 9215. [Abstract] [Full Text] [PDF]

				S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., December 9, 2004; 351(24): 2519 - 2529. [Full Text] [PDF]

				J. I. Geller and V. M. Santana Tumor Rupture and Mitotic Index in Pediatric Sex Cord-Stromal Tumors J. Clin. Oncol., May 15, 2004; 22(10): 2032 - 2033. [Full Text] [PDF]

				D. T. Schneider, G. Calaminus, and U. Gobel In Reply: J. Clin. Oncol., May 15, 2004; 22(10): 2033 - 2035. [Full Text] [PDF]